XBiotech Inc. Material Event - What Happened

Alright, let's break down what's going on with XBiotech Inc. in a way that makes sense, without all the fancy finance talk. Think of this as me explaining the news to you over coffee.

---

1. What happened?

Okay, so XBiotech is making a big change at the very top. John Simard, who has been the President and Chief Executive Officer (CEO) for a long time, is stepping down from his CEO role. But he's not leaving completely; he'll stay on as the Chairman of the Board of Directors. Taking his place, at least for now, is Sushma Shivaswamy, who has been the company's Chief Scientific Officer (CSO). She's been appointed as the interim CEO and will also continue to handle her CSO duties.

2. When did it happen?

Mr. Simard let the Board of Directors know about his decision on December 5, 2025. The changes, with Dr. Shivaswamy stepping into the interim CEO role, will officially take effect on December 8, 2025.

3. Why did it happen?

This change is happening because John Simard decided to retire from his CEO position. He's been a leader at XBiotech for an impressive 21 years, so it's a significant transition for him and the company. The Board is thanking him for his long service and leadership.

4. Why does this matter?

A change in the CEO role is always a big deal for any company. The CEO sets the vision and direction. While Mr. Simard is stepping down as CEO, his decision to remain as Chairman of the Board and to continue advising the company on its clinical, scientific, and strategic plans means there's still some continuity and his vast experience won't be lost entirely. Dr. Shivaswamy stepping in as interim CEO, while also keeping her Chief Scientific Officer role, shows the company is trying to maintain stability and leverage her scientific expertise during this transition period.

5. Who is affected?

Who's going to feel this the most?

• Employees: There might be some uncertainty with a leadership change, but the fact that the former CEO is staying on as Chairman and an internal person is stepping up as interim CEO might help ease concerns. Dr. Shivaswamy's dual role means she'll have a lot on her plate.
• Customers/Patients: For now, there's likely no direct immediate impact on patients or customers. The company's mission and ongoing projects should continue as planned, especially with Mr. Simard's continued advisory role.
• Investors (people who own stock): This is a significant leadership transition. Investors will be watching closely to see how the company manages this period and who is eventually appointed as the permanent CEO. Mr. Simard's continued involvement as Chairman and consultant might be seen as a positive sign of stability, but the interim nature of Dr. Shivaswamy's appointment means there's still a search for a long-term leader ahead.
• The Company Itself: XBiotech is entering a new chapter. It will need to manage the transition smoothly, find a permanent CEO, and ensure its strategic initiatives continue without interruption. Dr. Shivaswamy's annual base salary will increase to $750,000 while she serves in both roles, and Mr. Simard will receive a severance package and consulting fees, which are financial considerations for the company.

6. What happens next?

The company will now begin the process of finding a permanent Chief Executive Officer. In the meantime, Dr. Shivaswamy will lead XBiotech as interim CEO, continuing her work as Chief Scientific Officer. Mr. Simard will continue to support the company in his role as Chairman of the Board and as a consultant, providing guidance on key initiatives.

7. What should investors/traders know?

This is a major leadership transition for XBiotech. While the departure of a long-standing CEO can sometimes cause concern, Mr. Simard's continued presence as Chairman and consultant provides a degree of stability and continuity. The appointment of an internal leader, Dr. Shivaswamy, as interim CEO also suggests a smooth handover. However, the search for a permanent CEO will be a key event to watch. Investors should monitor updates on the CEO search and any potential shifts in the company's strategic direction once a permanent leader is in place.